648 related articles for article (PubMed ID: 12471615)
21. Survivin expression in ovarian cancer.
Liguang Z; Peishu L; Hongluan M; Hong J; Rong W; Wachtel MS; Frezza EE
Exp Oncol; 2007 Jun; 29(2):121-5. PubMed ID: 17704744
[TBL] [Abstract][Full Text] [Related]
22. Reduced Gonadotrophin Receptor Expression Is Associated with a More Aggressive Ovarian Cancer Phenotype.
Cheung J; Lokman NA; Abraham RD; Macpherson AM; Lee E; Grutzner F; Ghinea N; Oehler MK; Ricciardelli C
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374698
[TBL] [Abstract][Full Text] [Related]
23. FSH receptor binding inhibitor restrains follicular development and possibly attenuates carcinogenesis of ovarian cancer through down-regulating expression levels of FSHR and ERβ in normal ovarian tissues.
Zhuandi G; Tuanjie C; Luju L; Abdiryim A; Yingying D; Haoqin L; Suocheng W; Li D
Gene; 2018 Aug; 668():174-181. PubMed ID: 29783074
[TBL] [Abstract][Full Text] [Related]
24. Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression.
Behrens P; Rothe M; Florin A; Wellmann A; Wernert N
Int J Mol Med; 2001 Aug; 8(2):149-54. PubMed ID: 11445865
[TBL] [Abstract][Full Text] [Related]
25. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
26. [Expression of folate receptor alpha in ovarian epithelial tumors].
Shen DH; Xie JL; Zhang YL; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165
[TBL] [Abstract][Full Text] [Related]
27. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis.
Rutgers JL; Scully RE
Cancer; 1988 Jan; 61(2):340-8. PubMed ID: 3334969
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
[TBL] [Abstract][Full Text] [Related]
29. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
31. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
[TBL] [Abstract][Full Text] [Related]
32. A role for neurotransmitters in early follicular development: induction of functional follicle-stimulating hormone receptors in newly formed follicles of the rat ovary.
Mayerhofer A; Dissen GA; Costa ME; Ojeda SR
Endocrinology; 1997 Aug; 138(8):3320-9. PubMed ID: 9231784
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of claudin family proteins in mouse ovarian serous papillary epithelial adenoma in aging FSH receptor-deficient mutants.
Aravindakshan J; Chen X; Sairam MR
Neoplasia; 2006 Dec; 8(12):984-94. PubMed ID: 17217615
[TBL] [Abstract][Full Text] [Related]
34. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
[TBL] [Abstract][Full Text] [Related]
35. Neutral endopeptidase/CD10 expression in the stroma of epithelial ovarian carcinoma.
Khin EE; Kikkawa F; Ino K; Suzuki T; Shibata K; Kajiyama H; Tamakoshi K; Mizutani S
Int J Gynecol Pathol; 2003 Apr; 22(2):175-80. PubMed ID: 12649673
[TBL] [Abstract][Full Text] [Related]
36. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
[TBL] [Abstract][Full Text] [Related]
37. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
38. Loss of alternately spliced messenger RNA of the luteinizing hormone receptor and stability of the follicle-stimulating hormone receptor messenger RNA in granulosa cell tumors of the human ovary.
Reinholz MM; Zschunke MA; Roche PC
Gynecol Oncol; 2000 Nov; 79(2):264-71. PubMed ID: 11063655
[TBL] [Abstract][Full Text] [Related]
39. Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa?
Wolsky RJ; Price MA; Zaloudek CJ; Rabban JT
Int J Gynecol Pathol; 2018 May; 37(3):262-274. PubMed ID: 28700429
[TBL] [Abstract][Full Text] [Related]
40. Expression profile of heptahelical putative membrane progesterone receptors in epithelial ovarian tumors.
Romero-Sánchez M; Peiper SC; Evans B; Wang Z; Catasús L; Ribe A; Prat J; Giri JG
Hum Pathol; 2008 Jul; 39(7):1026-33. PubMed ID: 18479732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
